Skip to main content
Type at least 3 characters

29,800 articles

Brief Research Report

Published on 01 Feb 2023

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

in Multiple Sclerosis and Neuroimmunology

  • Pilar Santiago-Setien
  • Cristina Barquín-Rego
  • Paula Hernández-Martínez
  • María Ezquerra-Marigomez
  • Marta Torres-Barquin
  • Cristina Menéndez-Garcia
  • Fernando Uriarte
  • Yésica Jiménez-López
  • Mercedes Misiego
  • Jose Ramón Sánchez de la Torre
Frontiers in Immunology
doi 10.3389/fimmu.2023.1086028
  • 7,236 views
  • 3 citations

Original Research

Published on 01 Feb 2023

Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities

in Cytokines and Soluble Mediators in Immunity

  • Laura Almada
  • Sofía Carla Angiolini
  • Nicolás Daniel Dho
  • Jeremías Dutto
  • Yamila Gazzoni
  • Clarisa Manzone-Rodríguez
  • Constanza Marín
  • Nicolás Eric Ponce
  • Daniela Soledad Arroyo
  • Juan Nahuel Quiróz
Frontiers in Immunology
doi 10.3389/fimmu.2023.1111797
  • 4,448 views
  • 4 citations